Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 125

Sort by

Sort Order Select

Journal Articles

B Cell Receptor Silencing Reveals Origin and Impacts Treatment of High-Grade B Cell Lymphomas with MYC and BCL2 Rearrangements

Blood (2024) 144 (Supplement 1): 453.

https://doi.org/10.1182/blood-2024-203258

Published: 2024

Journal Articles

Venetoclax and Azacitidine for Relapse Prevention in NPM1 -Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial

Blood (2024) 144 (Supplement 1): 2893.

https://doi.org/10.1182/blood-2024-210315

Published: 2024

Journal Articles

Mantle cell lymphoma with IRTA1 + reactive expansion of the marginal zone

Brunangelo Falini, Stefano Lazzi

Blood (2024) 144 (2): 237.

https://doi.org/10.1182/blood.2024024808

Published: 2024

Journal Articles

Importance of FDG-PET (Fluorodeoxyglucose Positron Emission Tomography) in Staging and Response Assessment of Hairy Cell Leukemia (HCL)

Alessandro Mancini, Luca De Carolis, Monia Capponi, Flavio Falcinelli, Edoardo Simonetti, Andrea Lupi, Jacopo Olivieri, Francesco Zaja, Matteo Porcari, Nicodemo Baffa, Brunangelo Falini, Enrico Tiacci

Blood (2023) 142 (Supplement 1): 3044.

https://doi.org/10.1182/blood-2023-177603

Published: 2023

Journal Articles

Real-Life Efficacy and Safety of Vemurafenib Plus Rituximab (V+R) in Relapsed or Refractory Hairy Cell Leukemia: A Multi-Center Retrospective Study (HCL-PG03R)

Blood (2023) 142 (Supplement 1): 3027.

https://doi.org/10.1182/blood-2023-178648

Published: 2023

Journal Articles

Efficacy and Safety of Obinutuzumab in Relapsed or Refractory Hairy Cell Leukemia (R/R HCL): An Italian Multicenter Phase-2 Academic Trial (HCL-PG04)

Enrico Tiacci, Luca De Carolis, Monia Capponi, Flavio Falcinelli, Francesco Zaja, Alessandro Pulsoni, Edoardo Simonetti, Elisa Montechiarello, Alessandra Romano, Jacopo Olivieri, Alessandro Mancini, Gianna Maria D'Elia, Robin Foa, Maurizio Frezzato, Brunangelo Falini

Blood (2023) 142 (Supplement 1): 4398.

https://doi.org/10.1182/blood-2023-180035

Published: 2023

Journal Articles

Overlapping features of therapy-related and de novo NPM1 -mutated AML

Blood (2023) 141 (15): 1846–1857.

https://doi.org/10.1182/blood.2022018108

Published: 2023

Includes: Supplemental data

Journal Articles

B-cell prolymphocytic leukemia after COVID-19 infection

Brunangelo Falini, Stefano Lazzi

Blood (2023) 141 (14): 1777.

https://doi.org/10.1182/blood.2023019816

Published: 2023

Journal Articles

Diffuse large B-cell lymphoma of the testis

Brunangelo Falini, Stefano Lazzi

Blood (2022) 140 (24): 2645.

https://doi.org/10.1182/blood.2022018344

Published: 2022

Journal Articles

Pediatric large B-cell lymphoma with 11q aberration

Brunangelo Falini, Stefano Lazzi

Blood (2022) 140 (24): 2644.

https://doi.org/10.1182/blood.2022017409

Published: 2022

Journal Articles

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

Blood (2022) 140 (21): 2228–2247.

https://doi.org/10.1182/blood.2022015853

Published: 2022

Includes: Supplemental data

Journal Articles

Tuned IL3-Zetakine Coupled to a CD33 Costimulatory Receptor As a Dual CAR for Safer and Selective Targeting of Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 10237–10238.

https://doi.org/10.1182/blood-2022-166555

Published: 2022

Journal Articles

Epstein-Barr virus–positive mucocutaneous ulcer of the stomach

Brunangelo Falini, Stefano Lazzi

Blood (2022) 140 (15): 1743.

https://doi.org/10.1182/blood.2022017803

Published: 2022

Journal Articles

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Elias Campo, Elaine S. Jaffe, James R. Cook, Leticia Quintanilla-Martinez, Steven H. Swerdlow, Kenneth C. Anderson, Pierre Brousset, Lorenzo Cerroni, Laurence de Leval, Stefan Dirnhofer, Ahmet Dogan, Andrew L. Feldman, Falko Fend, Jonathan W. Friedberg, Philippe Gaulard, Paolo Ghia, Steven M. Horwitz, Rebecca L. King, Gilles Salles, Jesus San-Miguel, John F. Seymour, Steven P. Treon, Julie M. Vose, Emanuele Zucca, Ranjana Advani, Stephen Ansell, Wing-Yan Au, Carlos Barrionuevo, Leif Bergsagel, Wing C. Chan, Jeffrey I. Cohen, Francesco d’Amore, Andrew Davies, Brunangelo Falini, Irene M. Ghobrial, John R. Goodlad, John G. Gribben, Eric D. Hsi, Brad S. Kahl, Won-Seog Kim, Shaji Kumar, Ann S. LaCasce, Camille Laurent, Georg Lenz, John P. Leonard, Michael P. Link, Armando Lopez-Guillermo, Maria Victoria Mateos, Elizabeth Macintyre, Ari M. Melnick, Franck Morschhauser, Shigeo Nakamura, Marina Narbaitz, Astrid Pavlovsky, Stefano A. Pileri, Miguel Piris, Barbara Pro, Vincent Rajkumar, Steven T. Rosen, Birgitta Sander, Laurie Sehn, Margaret A. Shipp, Sonali M. Smith, Louis M. Staudt, Catherine Thieblemont, Thomas Tousseyn, Wyndham H. Wilson, Tadashi Yoshino, Pier-Luigi Zinzani, Martin Dreyling, David W. Scott, Jane N. Winter, Andrew D. Zelenetz

Blood (2022) 140 (11): 1229–1253.

https://doi.org/10.1182/blood.2022015851

Published: 2022

Includes: Supplemental data

Journal Articles

How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors

Brunangelo Falini, Luca De Carolis, Enrico Tiacci

Blood (2022) 139 (15): 2294–2305.

https://doi.org/10.1182/blood.2021013502

Published: 2022

Journal Articles

Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML

Blood (2021) 138 (25): 2696–2701.

https://doi.org/10.1182/blood.2021012732

Published: 2021

Includes: Supplemental data

Journal Articles

BCOR gene alterations in hematologic diseases

Paolo Sportoletti, Daniele Sorcini, Brunangelo Falini

Blood (2021) 138 (24): 2455–2468.

https://doi.org/10.1182/blood.2021010958

Published: 2021

Includes: Supplemental data

Journal Articles

CD123 and CD33 Co-Targeting By Balanced Signaling on CAR-CIK Cells Reduces Potential Off-Target Toxicity While Preserving the Anti-Leukemic Activity of Acute Myeloid Leukemia

Vincenzo Maria Perriello, Maria Caterina Rotiroti, Ilaria Pisani, Gaia Alberti, Giulia Pianigiani, Roberta Rossi, Valerio Ciaurro, Marta Serafini, Maria Paola Martelli, Brunangelo Falini, Andrea Biondi, Sarah Tettamanti

Blood (2021) 138 (Supplement 1): 1699.

https://doi.org/10.1182/blood-2021-150487

Published: 2021

Journal Articles

A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

Blood (2021) 138 (Supplement 1): 41.

https://doi.org/10.1182/blood-2021-146773

Published: 2021

Journal Articles

How I diagnose and treat NPM1 -mutated AML

Brunangelo Falini, Lorenzo Brunetti, Maria Paola Martelli

Blood (2021) 137 (5): 589–599.

https://doi.org/10.1182/blood.2020008211

Published: 2021

NARROW

B Cell Receptor Silencing Reveals Origin and Impacts Treatment of High-Grade B Cell Lymphomas with MYC and BCL2 Rearrangements

Venetoclax and Azacitidine for Relapse Prevention in NPM1 -Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial

Mantle cell lymphoma with IRTA1 + reactive expansion of the marginal zone

Importance of FDG-PET (Fluorodeoxyglucose Positron Emission Tomography) in Staging and Response Assessment of Hairy Cell Leukemia (HCL)

Real-Life Efficacy and Safety of Vemurafenib Plus Rituximab (V+R) in Relapsed or Refractory Hairy Cell Leukemia: A Multi-Center Retrospective Study (HCL-PG03R)

Efficacy and Safety of Obinutuzumab in Relapsed or Refractory Hairy Cell Leukemia (R/R HCL): An Italian Multicenter Phase-2 Academic Trial (HCL-PG04)

Overlapping features of therapy-related and de novo NPM1 -mutated AML

B-cell prolymphocytic leukemia after COVID-19 infection

Diffuse large B-cell lymphoma of the testis

Pediatric large B-cell lymphoma with 11q aberration

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

Tuned IL3-Zetakine Coupled to a CD33 Costimulatory Receptor As a Dual CAR for Safer and Selective Targeting of Acute Myeloid Leukemia

Epstein-Barr virus–positive mucocutaneous ulcer of the stomach

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors

Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML

BCOR gene alterations in hematologic diseases

CD123 and CD33 Co-Targeting By Balanced Signaling on CAR-CIK Cells Reduces Potential Off-Target Toxicity While Preserving the Anti-Leukemic Activity of Acute Myeloid Leukemia

A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

How I diagnose and treat NPM1 -mutated AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only